TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01092741
Drug: Gleevec
Normalized name: Gleevec
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400 mg P.O. twice daily (800 mg total daily dose)
Study: NCT00192647
Drug: PEG-IFN alfa-2a
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
Study: NCT00192647
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
Study: NCT04682444
Drug: Enisamium Iodide
Normalized name: enisamium iodide
DrugBank: Iodide (DB12754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients ingested Amizon tablets after meal without chewing as follows: 2 tablets (total dose 0.5 g) 3 times a day, for 7 days. Each tablet contains 0.25 g of Nmethyl- 4-N-methyl-4-benzylcarbamidopyridinium iodide (INN enisamium iodide).
Study: NCT01466361
Drug: Nicotine lower dose
Normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lower dose nicotine lozenge
Study: NCT01466361
Drug: Nicotine higher dose
Normalized name: nicotine Metered Dose Nasal Spray
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: higher dose nicotine lozenge
Study: NCT01593332
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: two 500 mg rituximab infusions 2 weeks apart
Study: NCT01593332
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500mg,two times with two weeks interval
Study: NCT01153672
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03847571
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
Study: NCT01290315
Drug: Ferric Carboxymaltose (FCM)
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
Study: NCT02275832
Drug: 3 % Minoxidil lotion
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03284047
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Participants will be randomized to one of three botulinum toxin type A doses.
Study: NCT01153672
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01153672
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01153672
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00934375
Drug: Aricept (donepezil hydrochloride)
Normalized name: donepezil hydrochloride Oral Tablet [Aricept]
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
Study: NCT01159587
Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Normalized name: factor VIII Injection [Recombinate]
DrugBank: PEGylated Recombinant Factor VIII (DB16093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly
Study: NCT01159587
Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Normalized name: factor VIII Injection [Recombinate]
DrugBank: PEGylated Recombinant Factor VIII (DB16093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment with product given only for bleeding episodes
Study: NCT00995969
Drug: CT 327
Normalized name: CT 179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
Study: NCT01813929
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
Study: NCT02262897
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
Study: NCT01851993
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01094288
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib ECT
Study: NCT01094288
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel IV infusion
Study: NCT03159403
Drug: Oritavancin
Normalized name: Oritavancin
DrugBank: Oritavancin (DB04911)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
Study: NCT00199953
Drug: Rabeprazole 20 mg twice a day for 90-day period treatment
Normalized name: rabeprazole sodium 20 MG
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02283788
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00239343
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01556477
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
Study: NCT01556477
Drug: azacitidine + lenalidomide
Normalized name: Azacitidine
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.~Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks.
Study: NCT03911193
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.
Study: NCT04482686
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment days 1, 4, and 8
Study: NCT02245737
Drug: Lanabecestat
Normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01970345
Drug: IGF-1
Normalized name: VEXXON-IGF-1
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
Study: NCT00905372
Drug: LY2062430
Normalized name: LY2062430
DrugBank: Solanezumab (DB11756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg intravenously (IV) every 4 weeks for 80 weeks
Study: NCT05221593
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg tablet in controlled released formula
Study: NCT03174964
Drug: IVIg
Normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take a dose of 400mg/kg of IVIg 2 days before ET.
Study: NCT03012880
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03012880
Drug: Ixazomib Citrate
Normalized name: Ixazomib citrate
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03012880
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03540979
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aromatase inhibitor - 2.5mg/d for 5 days
Study: NCT03540979
Drug: Ovidrel
Normalized name: Ovidrel
DrugBank: Choriogonadotropin alfa (DB00097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: recommbinant hCG 250 mcg- single sc injection to induce ovulation
Study: NCT03540979
Drug: Estrofem
Normalized name: ESTROFEM
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrofem 2mg\*3/d for endometrial preparation
Study: NCT02069704
Drug: Bevacizumab biosimilar (BEVZ92)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.
Study: NCT06325943
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive two doses of rituximab 1 g at two-week interval and one dose of rituximab 1 g at month 6
Study: NCT00892073
Drug: Diazoxide
Normalized name: Diazoxide
DrugBank: Diazoxide (DB01119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
Study: NCT00892073
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
Study: NCT03756987
Drug: Ropivacaine Injection
Normalized name: ROPivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine will be injected in the erector spinae plane
Study: NCT01236365
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 or 20 mg daily
Study: NCT01236365
Drug: Atorvastatin Placebo
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 or 20 mg daily
Study: NCT00148512
Drug: 1. Tesofensine (NS 2330)
DrugBank: Tesofensine (DB06156)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02443090
Drug: fispemifene
Normalized name: Fispemifene
DrugBank: Fispemifene (DB06640)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00700258
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Non-interventional study. Treatment decision already made before inclusion into the registry.
Study: NCT00700258
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Non-interventional study. Treatment decision already made before inclusion into the registry.
Study: NCT00700258
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-interventional study. Treatment decision already made before inclusion into the registry.
Study: NCT00821574
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan: daily 160 mg, oral
Study: NCT00821574
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide: daily 12.5mg, oral
Study: NCT04401852
Drug: MgSo4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.
Study: NCT02703051
Drug: GMI-1271
Normalized name: GMI-1070
DrugBank: Rivipansel (DB12778)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02703051
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03735810
Drug: LBS-008
Normalized name: spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LBS-008 oral capsules
Study: NCT01147601
Drug: topical 0.5% Timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily
Study: NCT02381600
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental :~1. Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~2. Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~3. At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.
Study: NCT03403933
Drug: Didrogyl
Normalized name: etidronate disodium Injectable Solution [Didronel]
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels\> 30 ng / ml are obtained.~Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study.
Study: NCT01248065
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
Study: NCT01248065
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
Study: NCT04218760
Drug: Isosorbide Mononitrate 60 MG Extended Release Oral Tablet [Imdur]
Normalized name: isosorbide mononitrate 60 MG Extended Release Oral Tablet [Imdur]
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet Isosorbide Mononitrate 60 mg administrated orally.
Study: NCT00002987
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002987
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02169830
Drug: nortriptyline
Normalized name: Nortriptyline
DrugBank: Nortriptyline (DB00540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
Study: NCT01493843
Drug: pictilisib
Normalized name: Pictilisib
DrugBank: Pictilisib (DB11663)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
Study: NCT01493843
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
Study: NCT01493843
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
Study: NCT01493843
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered at 200 milligrams per square meter (mg/m\^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
Study: NCT01474434
Drug: pradigastat (LCQ908)
Normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
Study: NCT02169830
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
Study: NCT04596527
Drug: 18F-FMPP
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-FMPP were injected into the patients at rest (2.5 mCi) and during stress (6.0 mCi) for an individual subject before PET/CT scans.
Study: NCT01841931
Drug: Buprenorphine/Naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).
Study: NCT00168623
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04224571
Drug: Bortezomib Injection
Normalized name: bortezomib Injection
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib: patients with BM relapsed, add for 4 doses on D1,4,7, 11 in induction; dosage 1.3 mg/m2/dose as per parenteral;
Study: NCT04224571
Drug: rituximab injection
Normalized name: rituximab Injection
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Add rituximab in patients with CD20 positive ALL, rituximab: 6 doses of on D8,11of induction, D1,15 of consolidation1 and 2 with dosage 375 mg/m2 as parenteral (Terminated in Oct 2020)
Study: NCT00355199
Drug: Rituximab-HDS
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-HDS
Study: NCT00355199
Drug: Rituximab-CHOP
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab-CHOP
Study: NCT03487354
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol
Study: NCT04451174
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 40 mg days 1 to 4. Then, prednisone 20 mg days 5 to 8.
Study: NCT00158860
Drug: Valaciclovir
Normalized name: valaciclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1g once daily
Study: NCT04049201
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Midazolam
Study: NCT00489723
Drug: tamsulosin 0.4mg
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02428764
Drug: Nimotuzumab
Normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
Study: NCT02428764
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
Study: NCT00777803
Drug: OnabotulinumtoxinA (Vistabel®)
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
Study: NCT02428764
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
Study: NCT03500159
Drug: AQX-1125 200 mg
Normalized name: AQX-1125
DrugBank: AQX-1125 (DB13012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic SHIP1 activator
Study: NCT03704714
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO